Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis

European Journal of Clinical Pharmacology

Volumn 52, Issue 5, 1997, Pages 397-401

  Castelli, F ^a   Tomasoni, L ^b   Zeroli, C ^c   Suter, F ^d   Trespi, G ^e   Carosi, G ^a   Hedman, A ^f  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Second Division of Infectious Diseases   (Italy)

^c Varese Hospital   (Italy)

^d BUSTO ARSIZIO HOSPITAL   (Italy)

^e Medical Department   (Italy)

^f Department of Clinical Pharmacology ^*  (Sweden)

Author keywords

Cytomegalovirus (CMV); Dosage regimens; Foscarnet; HIV

Indexed keywords

CALCIUM ION; FOSCARNET;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG HALF LIFE; ELECTROCARDIOGRAM; ELECTROLYTE BALANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RETINITIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CALCIUM; CYTOMEGALOVIRUS RETINITIS; ELECTROCARDIOGRAPHY; FEMALE; FOSCARNET; HUMANS; KIDNEY FUNCTION TESTS; MALE;

EID: 0030757473     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050308     Document Type: Article

References (24)

1. Drew WL (1992) Cytomegalovirus infection in patients with AIDS. Clin Inf Dis 14: 608
2. Fanning MM, Read SE, Benson M, Vas S, Radius A, Kozousek V, Mortimer C, Harvey P, Schwartz C, Chew E, Brunton J, Matlow A, Salit I, Vellend H, Walmsley S (1990) Foscarnet therapy of Cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr 3: 472
3. Jacobson MA, O'Donnell JJ, Mills J (1989) Foscarnet treatment of Cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 33: 736
4. Katlama C, Dohin E, Caumes E, Cochereau-Massin I, Brancon C, Robinet M, Rogeaux O, Dahan R, Gentilini M (1992) Foscarnet induction therapy for Cytomegalovirus retinitis in AIDS: comparison of twice daily and three times daily regimens. J Acquir Immune Defic Syndr 5 (Suppl 1): S18
5. Taburet AM, Katlama C, Blanshard C, Zorza G, Gazzard D, Dohin E, Gazzard BG, Frostegård C, Singlas E (1992) Pharmacokinetics of foscarnet after twice daily administration for treatment of Cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother 36: 1821
6. Pettersson KJ, Nordgren T, Westerlund D (1989) Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. J Chromatogr 488: 447
7. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
8. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31
9. Chrisp P, Clissold SP (1991) Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with Cytomegalovirus retinitis. Drugs 41: 104
10. Sjövall J, Karlsson A, Ogenstad S, Sandström E, Saarimaki M (1988) Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 44: 65
11. Sjövall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 33: 1023
12. Aweeka FT, Gambertoglio JG, Mills J, Jacobson MA (1989) Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious Cytomegalovirus retinitis. Antimicrob Agents Chemother 33: 742
13. Frostegård C, Arvidsson A (1992) Pharmacokinetic properties of foscarnet: a review. Third European conference on clinical aspects and treatment of HIV infections. Paris, 12-13 March 1992, abs P9
14. Palestine AG, Polis MA, De Smet MD, Baird BF, et al. (1991) A randomized controlled trial of foscarnet in the treatment of Cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 115: 665
15. Aweeka FT, Omachi R, Jacobson MA, Schoenfeld P, Martin-Munley S, Gambertoglio J (1993) Pharmacokinetics of foscarnet in patients with varying degrees of renal function. IX Int. Conf. AIDS. Berlin, 7-11 June 1993, abs 2097
16. Gaub J, Pedersen C, Poulsen A-G, Mathiesen LR, Ulrich K, Lindhardt BO, Faber V, Gerstoft J, Hofmann B, Lernestedt J-O, Nielsen CM, Nielsen JO, Platz P (1987) The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1: 27
17. Walmsley SL, Chew E, Read SE, Vellend H, Salit I, Rachlis A, Fanning MM (1988) Treatment of Cytomegulovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 157: 569]
18. Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, Rozenheim M, Baumelou A, Dohin E, Gentium M, Jacobs C (1989) Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 9: 316
19. Deray G, Katlama C, Dohin E (1990) Prevention of foscarnet nephrotoxicity. Ann Intern Med 113: 332
20. Carosi G, Castelli F and the Italian Foscarnet Retinitis Study Group (1993) A randomized controlled trial of two dosage regimens of foscarnet in AIDS patients with CMV retinitis. IX Int. Conf. AIDS. Berlin. 7 11 June 1993, abs WS-B11-3
21. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA (1991) Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metabol 72: 1130
22. Ryrfeldt Å, Nordgren T, Lundström J (1992) Hypocalcemia induced by foscarnet (Foscavir ®) infusion in dogs. Fund Appl Toxicol 18: 126
23. Scheidegger D, Drop LJ (1979) The relation between duration of QT interval and plasma ionized calcium concentration. Anaestesiol 51: 143
24. Gerhart MO, Sorg TB (1993) Foscarnet-induced severe hypomaenesemia and other electrolyte disorders. Ann Pharmacother 27: 285